Should investors be concerned about Neuphoria Therapeutics Inc (NEUP)?

Arcelia Reed

While Neuphoria Therapeutics Inc has overperformed by 3.97%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NEUP rose by 37.32%, with highs and lows ranging from $21.40 to $2.12, whereas the simple moving average fell by -36.39% in the last 200 days.

On September 28, 2023, H.C. Wainwright Upgraded Neuphoria Therapeutics Inc (NASDAQ: NEUP) to Buy. A report published by Maxim Group on September 28, 2023, Reiterated its previous ‘Buy’ rating for NEUP. H.C. Wainwright also rated NEUP shares as ‘Buy’, setting a target price of $54 on the company’s shares in an initiating report dated January 10, 2022. Evercore ISI Initiated an Outperform rating on January 10, 2022, and assigned a price target of $17. Cantor Fitzgerald initiated its ‘Overweight’ rating for NEUP, as published in its report on January 10, 2022. Berenberg’s report from January 10, 2022 suggests a price prediction of $21 for NEUP shares, giving the stock a ‘Buy’ rating.

Analysis of Neuphoria Therapeutics Inc (NEUP)

There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Neuphoria Therapeutics Inc’s future performance, with equity being one of the most critical indicators. Taking into account the quick ratio of the company, currently set at 11.01, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

As an indicator of volatility for any stock, average volume can also be very valuable, and NEUP is recording an average volume of 1.46M. On a monthly basis, the volatility of the stock is set at 16.75%, whereas on a weekly basis, it is put at 23.98%, with a loss of -2.89% over the past seven days. Furthermore, long-term investors anticipate a median target price of $19.43, showing growth from the present price of $4.71, which can serve as yet another indication of whether NEUP is worth investing in or should be passed over.

How Do You Analyze Neuphoria Therapeutics Inc Shares?

Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 4.70%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 52.52% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.